$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph

$usph Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000114036122028661 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$139.6M	$140.7M	$129.8M
YoY Change	12.96%	10.82%	10.5%
Cost Of Revenue	$112.8M	$109.8M	$102.6M
YoY Change	17.41%	18.55%	16.24%
Gross Profit	$26.78M	$30.82M	$27.19M
YoY Change	-10.12%	-10.15%	-6.55%
Gross Profit Margin	19.19%	21.91%	20.94%
Selling, General & Admin	$11.89M	$10.74M	$10.72M
YoY Change	-7.6%	-11.04%	-1.67%
% of Gross Profit	44.39%	34.85%	39.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.652M	$3.474M	$3.072M
YoY Change	20.33%	23.89%	24.88%
% of Gross Profit	13.64%	11.27%	11.3%
Operating Expenses	$11.89M	$10.74M	$10.72M
YoY Change	-7.6%	-11.04%	-1.67%
Operating Profit	$14.90M	$20.08M	$16.48M
YoY Change	-12.03%	-9.67%	-9.48%
Interest Expense	-$1.644M	$32.00K	-$38.00K
YoY Change	682.86%	-116.75%	-81.0%
% of Operating Profit	-11.04%	0.16%	-0.23%
Other Income/Expense, Net	$2.785M	-$585.0K	$0.00
YoY Change	129.03%	206.28%
Pretax Income	$16.04M	$19.50M	$18.39M
YoY Change	-10.6%	-11.54%	-20.74%
Income Tax	$3.215M	$4.239M	$3.946M
% Of Pretax Income	20.05%	21.74%	21.46%
Net Earnings	$9.557M	$11.20M	$10.21M
YoY Change	-4.52%	-9.98%	-21.44%
Net Earnings / Revenue	6.85%	7.96%	7.87%
Basic Earnings Per Share	$0.72	$0.87
Diluted Earnings Per Share	$735.1K	$0.87	$791.1K
COMMON SHARES
Basic Shares Outstanding	13.00M	13.00M	12.91M
Diluted Shares Outstanding	13.00M	13.00M

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.91M	$48.57M	$28.57M
YoY Change	97.59%	137.88%	-13.17%
Cash & Equivalents	$37.91M	$48.57M	$28.57M
Short-Term Investments
Other Short-Term Assets	$6.085M	$3.810M	$4.183M
YoY Change	65.04%	-25.45%	10.87%
Inventory
Prepaid Expenses
Receivables	$68.89M	$50.55M	$46.27M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$112.9M	$121.8M	$95.17M
YoY Change	42.14%	52.88%	8.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$126.0M	$24.23M	$22.98M
YoY Change	9.55%	-77.7%	6.07%
Goodwill	$449.5M	$442.8M	$434.7M
YoY Change	20.18%	18.42%	25.76%
Intangibles	$93.70M	$92.66M	$86.38M
YoY Change	55.94%	56.47%	53.49%
Long-Term Investments	$11.98M	$12.35M	$12.22M
YoY Change
Other Assets	$5.619M	$1.333M	$1.578M
YoY Change	261.82%	-11.49%	2.53%
Total Long-Term Assets	$686.8M	$674.6M	$654.3M
YoY Change	24.72%	0.73%	29.12%
TOTAL ASSETS
Total Short-Term Assets	$112.9M	$121.8M	$95.17M
Total Long-Term Assets	$686.8M	$674.6M	$654.3M
Total Assets	$799.7M	$796.4M	$749.4M
YoY Change	26.92%	6.27%	26.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.674M	$6.996M	$6.471M
YoY Change	400.91%	292.59%	397.77%
Accrued Expenses	$66.32M	$41.25M	$45.71M
YoY Change	31.94%	-7.77%	-23.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.490M	$4.780M	$830.0K
YoY Change	1014.58%	370.01%	-83.06%
Total Short-Term Liabilities	$81.49M	$85.11M	$83.48M
YoY Change	-0.22%	12.9%	-10.71%
LONG-TERM LIABILITIES
Long-Term Debt	$146.7M	$148.9M	$117.6M
YoY Change	315.96%	283.53%	608.53%
Other Long-Term Liabilities	$80.93M	$4.858M	$7.345M
YoY Change	4.23%	-93.28%	61.82%
Total Long-Term Liabilities	$227.6M	$153.7M	$124.9M
YoY Change	545.46%	296.04%	491.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.49M	$85.11M	$83.48M
Total Long-Term Liabilities	$227.6M	$153.7M	$124.9M
Total Liabilities	$482.6M	$336.1M	$297.0M
YoY Change	41.8%	-0.88%	61.06%
SHAREHOLDERS EQUITY
Retained Earnings	$235.7M	$232.2M	$224.4M
YoY Change	7.45%		5.84%
Common Stock	$152.0K	$152.0K	$151.0K
YoY Change			0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$31.63M	$31.63M	$31.63M
YoY Change			0.0%
Treasury Stock Shares	$2.215M	$2.215M	$2.215M
Shareholders Equity	$317.1M	$307.2M	$295.6M
YoY Change
Total Liabilities & Shareholders Equity	$799.7M	$796.4M	$749.4M
YoY Change	26.92%	27.85%	26.09%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	$9.557M	$11.20M	$10.21M
YoY Change	-4.52%	-9.98%	-21.44%
Depreciation, Depletion And Amortization	$3.652M	$3.474M	$3.072M
YoY Change	20.33%	23.89%	24.88%
Cash From Operating Activities	$13.73M	$15.86M	$15.91M
YoY Change	-44.97%	-11.32%	-37.38%
INVESTING ACTIVITIES
Capital Expenditures	-$2.721M	-$2.041M	-$2.205M
YoY Change	0.96%	20.7%	2.56%
Acquisitions
YoY Change
Other Investing Activities	-$11.62M	-$5.555M	-$77.67M
YoY Change	41.88%	-69.93%	197.14%
Cash From Investing Activities	-$14.34M	-$7.596M	-$79.88M
YoY Change	31.75%	-62.35%	182.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.05M	16.08M	73.35M
YoY Change	-34.3%	237.04%	1189.14%
NET CHANGE
Cash From Operating Activities	13.73M	15.86M	15.91M
Cash From Investing Activities	-14.34M	-7.596M	-79.88M
Cash From Financing Activities	-10.05M	16.08M	73.35M
Net Change In Cash	-10.66M	24.34M	9.379M
YoY Change	765.8%	881.18%	233.77%
FREE CASH FLOW
Cash From Operating Activities	$13.73M	$15.86M	$15.91M
Capital Expenditures	-$2.721M	-$2.041M	-$2.205M
Free Cash Flow	$16.45M	$17.90M	$18.11M
YoY Change	-40.49%	-8.55%	-34.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000885978
	usph	Proceeds From Sales Of Non Controlling Interest Permanent ProceedsFromSalesOfNonControllingInterestPermanent	344000
	usph	Proceeds From Sales Of Non Controlling Interest Permanent ProceedsFromSalesOfNonControllingInterestPermanent	32000
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	1000000
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	287000
CY2022Q2	us-gaap	Interest Rate Derivative Liabilities At Fair Value InterestRateDerivativeLiabilitiesAtFairValue	500000
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2555
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.2555
CY2022Q2	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	54000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	140656000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126928000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	272360000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	239296000
	usph	Estimated Percentage Of Decrease In Payment EstimatedPercentageOfDecreaseInPayment	0.035
CY2021Q4	usph	Percentage Of Reduction In Medicare Payments For Services Performed By A Physical Or Occupational Therapist PercentageOfReductionInMedicarePaymentsForServicesPerformedByAPhysicalOrOccupationalTherapist	0.15
	usph	Period Of Federal Debt Ceiling In Connection With Deficit Reductions PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions	P10Y
	usph	Amount Of Reductions In Federal Spending AmountOfReductionsInFederalSpending	1200000000000
	usph	Reduction In Medicare Spending Percentage ReductionInMedicareSpendingPercentage	0.02
CY2013Q2	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2015Q4	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2018Q1	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2022Q2	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2022Q2	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2021Q2	usph	Percentage Of Payment Reduction Waived Through Enacted Legislation PercentageOfPaymentReductionWaivedThroughEnactedLegislation	0.02
	usph	Extension Term For Sequester Relief Applied To All Medicare Payments ExtensionTermForSequesterReliefAppliedToAllMedicarePayments	P3M
CY2021Q4	usph	Percentage Of Sequester Relief Applied To All Medicare Payments Through Period One PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodOne	0.02
CY2021Q4	usph	Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo	0.01
	usph	Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem	0.01
	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
	usph	Reduction In Combined Physical Therapy Speech Language Pathology Expenses ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses	3000
	usph	Percentage Of Practice Expense Component Of Relative Value Unit PercentageOfPracticeExpenseComponentOfRelativeValueUnit	1
	usph	Percentage Reduction For Service In Office Or Other Non Institutional Settings PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings	0.50
	usph	Percentage Of Payment For Outpatient Therapy Services PercentageOfPaymentForOutpatientTherapyServices	0.85
	usph	Net Revenue From Medicare NetRevenueFromMedicare	74900000
	usph	Net Revenue From Medicare NetRevenueFromMedicare	62100000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	11195000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	12436000
	us-gaap	Net Income Loss NetIncomeLoss	19994000
	us-gaap	Net Income Loss NetIncomeLoss	20609000
CY2022Q2	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	210000
CY2021Q2	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	-2549000
	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	57000
	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	-9819000
CY2021Q2	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	-651000
	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	15000
	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	-2508000
CY2022Q2	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	11351000
CY2021Q2	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	10538000
	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	20036000
	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	13298000
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12998000
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12998000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12902000
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12902000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12968000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12968000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12886000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12886000
CY2021Q4	us-gaap	Goodwill Goodwill	434679000
CY2020Q4	us-gaap	Goodwill Goodwill	345646000
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12114000
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	89746000
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-4032000
CY2021	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-713000
CY2022Q2	us-gaap	Goodwill Goodwill	442761000
CY2021Q4	us-gaap	Goodwill Goodwill	434679000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	92655000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	86382000
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1459000
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	916000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3278000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1738000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0
CY2021Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	118417000
CY2022Q2	usph	Debt Instrument Face Amount Current DebtInstrumentFaceAmountCurrent	5188000
CY2022Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	408000
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	4780000
CY2021Q4	usph	Debt Instrument Face Amount Current DebtInstrumentFaceAmountCurrent	830000
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	0
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	830000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19524000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23569000
CY2022Q2	usph	Patients And Payors Related Liability PatientsAndPayorsRelatedLiability	7875000
CY2021Q4	usph	Patients And Payors Related Liability PatientsAndPayorsRelatedLiability	6649000
CY2022Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	2038000
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1984000
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	285000
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	498000
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	1754000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2716000
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1000000
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1000000
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2750000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8770000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6539000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41246000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45705000
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	2750000
CY2021	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	2600000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	155696000
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2027000
CY2022Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	153669000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	118417000
CY2022Q2	usph	Debt Instrument Face Amount Noncurrent DebtInstrumentFaceAmountNoncurrent	150508000
CY2022Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1619000
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	148889000
CY2021Q4	usph	Debt Instrument Face Amount Noncurrent DebtInstrumentFaceAmountNoncurrent	117587000
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	117587000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	8700000
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	7895000
	us-gaap	Operating Lease Cost OperatingLeaseCost	17104000
	us-gaap	Operating Lease Cost OperatingLeaseCost	15624000
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	259000
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	361000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	580000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	729000
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	1994000
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	1628000
	us-gaap	Variable Lease Cost VariableLeaseCost	3926000
	us-gaap	Variable Lease Cost VariableLeaseCost	3239000
CY2022Q2	us-gaap	Lease Cost LeaseCost	10953000
CY2021Q2	us-gaap	Lease Cost LeaseCost	9884000
	us-gaap	Lease Cost LeaseCost	21610000
	us-gaap	Lease Cost LeaseCost	19592000
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	8940000
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	8258000
	us-gaap	Operating Lease Payments OperatingLeasePayments	17557000
	us-gaap	Operating Lease Payments OperatingLeasePayments	16370000
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	15595000
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12976000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21606000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20873000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	17829000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	31725000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25292000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18060000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11613000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11135000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	115654000
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5795000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	109859000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M8D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M9D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M8D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M9D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0248
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0248
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030
CY2022Q2	us-gaap	Revenues Revenues	140656000
CY2021Q2	us-gaap	Revenues Revenues	126928000
	us-gaap	Revenues Revenues	272360000
	us-gaap	Revenues Revenues	239296000
CY2022Q2	us-gaap	Gross Profit GrossProfit	30821000
CY2021Q2	us-gaap	Gross Profit GrossProfit	34304000
	us-gaap	Gross Profit GrossProfit	57409000
	us-gaap	Gross Profit GrossProfit	60200000
CY2022Q2	us-gaap	Assets Assets	796444000
CY2021Q2	us-gaap	Assets Assets	749426000
CY2009Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	859499
	usph	Additional Estimated Repurchase Of Common Stock AdditionalEstimatedRepurchaseOfCommonStock	137363
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	109.20
CY2022Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0

Files In Submission

Name	View Source	Status
0001140361-22-028661-index-headers.html	Edgar Link	pending
0001140361-22-028661-index.html	Edgar Link	pending
0001140361-22-028661.txt	Edgar Link	pending
0001140361-22-028661-xbrl.zip	Edgar Link	pending
brhc10040351_10q.htm	Edgar Link	pending
brhc10040351_ex31-1.htm	Edgar Link	pending
brhc10040351_ex31-2.htm	Edgar Link	pending
brhc10040351_ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
usph-20220630.xsd	Edgar Link	pending
usph-20220630_lab.xml	Edgar Link	unprocessable
usph-20220630_cal.xml	Edgar Link	unprocessable
usph-20220630_pre.xml	Edgar Link	unprocessable
brhc10040351_10q_htm.xml	Edgar Link	completed
usph-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph

2022 Q3 Form 10-Q Financial Statement

#000114036122028661 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USPH U S PHYSICAL THERAPY INC /NV Stock $usph

2022 Q3 Form 10-Q Financial Statement

#000114036122028661 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph